Brief: Mabion Signs Statement Of Work With Novavax
June 8 (Reuters) - Mabion SA MABP.WA :
* SIGNS WITH NOVAVAX ANOTHER EXPANSION TO PRODUCTION DEAL IN
FORM
OF STATEMENT OF WORK
* WORKS UNDER STATEMENT OF WORK WILL START IMMEDIATELY AND
END IN
2022
* EXPANSION OF COLLABORATION REGARDS RESEARCH OF SARS COV-2
RS
SUBSTANCE (ELEMENT OF NUVAXOVID VACCINE)
Source text for Eikon: ID:nEM2yYXp5a
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys